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Abstract
Background: To guide future need for cheap resistance tests for use in low income settings, we assessed cost-effectiveness
of drug resistance testing as part of monitoring of people on first line ART - with switching from first to second line ART
being conditional on NNRTI drug resistance mutations being identified.
Methods: An individual level simulation model of HIV transmission, progression and the effect of ART which accounts for
adherence and resistance development was used to compare outcomes of various potential monitoring strategies in a
typical low income setting in sub-Saharan Africa. Underlying monitoring strategies considered were based on clinical
disease, CD4 count or viral load. Within each we considered a strategy in which no further measures are performed, one
with a viral load measure to confirm failure, and one with both a viral load measure and a resistance test. Predicted
outcomes were assessed over 2015–2025 in terms of viral suppression, first line failure, switching to second line regimen,
death, HIV incidence, disability-adjusted-life-years averted and costs. Potential future low costs of resistance tests ($30) were
used.
Results: The most effective strategy, in terms of DALYs averted, was one using viral load monitoring without confirmation.
The incremental cost-effectiveness ratio for this strategy was $2113 (the same as that for viral load monitoring with
confirmation). ART monitoring strategies which involved resistance testing did not emerge as being more effective or cost
effective than strategies not using it. The slightly reduced ART costs resulting from use of resistance testing, due to less use
of second line regimens, was of similar magnitude to the costs of resistance tests.
Conclusion: Use of resistance testing at the time of first line failure as part of the decision whether to switch to second line
therapy was not cost-effective, even though the test was assumed to be very inexpensive.
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Introduction
Approximately 10 million people worldwide are currently
receiving antiretroviral therapy (ART) [1] which, when effective
at suppressing HIV viral replication, is of benefit both in reversing
immunodeficiency and reducing infectiousness. WHO guidelines
recommend a first line regimen consisting of a non-nucleoside
reverse transcriptase inhibitor (NNRTI) efavirenz plus two
nucleoside analogue reverse transcriptase inhibitors (NRTI),
tenofovir and 3TC/FTC, with a second line regimen consisting
of a ritonavir boosted protease inhibitor (bPI) (lopinavir or
atazanair) plus two NRTIs (most commonly zidovudine and
3TC/FTC) [2]. Lack of viral suppression in a person who has
been on ART over 6 months suggests that either virus with drug
resistance has emerged, and possibly was already present at
infection, that adherence to the regimen is poor, or a combination
of these [3,4]. If resistance to the NNRTI drug is present there is a
clear need to switch to a second line regimen.
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There are marked differences between high and low income
countries in how people on ART are monitored in order to
identify the need to switch treatment. In high income settings,
people are monitored with measurement of the plasma HIV viral
load at approximately 3–6 monthly intervals and where viral load
is not suppressed a drug resistance test is done to detect presence of
resistance mutations [5,6]. If resistance is detected this indicates
that a second line regimen is needed. If resistance is not detected
then on-going lack of adherence is strongly suspected and
interventions to try to improve adherence are recommended
[5,6]. Some guidelines nevertheless recommend switching to a
second line regimen in such patients (i.e. a switch is indicated in
those with non-suppressed viral load regardless of the result of the
resistance test), due to the fact that ritonavir boosted PI regimens
are associated with lower risk of resistance than NNRTI regimens
in people who are inconsistently adherent [5].
Although guidelines in many countries are changing and viral
load testing is being introduced, most low income countries do not
yet have access to viral load measures for the majority of people on
ART, and resistance testing is hardly available at all. Decisions
whether to switch to second line regimens are made based on
clinical criteria, if a new WHO stage 3 or 4 condition occurs, or, if
available, on the CD4 count [2], both of which are indirect
measures of whether the first line regimen remains active.
Randomized trials have attempted to ascertain the consequences
of providing ART without viral load monitoring [7–12]. They
have generally found no more than modest differences, both for
the outcome of generation of drug resistance and mortality. In
contrast, modelling studies have generally indicated that use of
viral load monitoring is likely to be associated with some survival
benefit, albeit at a level that does not currently make it a cost
effective intervention in the most resource limited settings [13–20].
This lack of cost-effectiveness of viral load monitoring is due to the
cost of current viral load tests but also the cost of second line
regimens. Cheaper viral load measurements should become
available in the near future, either as point of care tests or using
dried blood spots. WHO guidelines recommend that countries
adopt viral load monitoring [2], but recognize this should not
compromise ART scale-up when treatment gaps exist. Further,
costs of second line drugs have been falling, with ritonavir boosted
atazanavir now available at $219 per person-year in some settings,
representing a drop of around two thirds in cost of a boosted PI
within five years [21].
Against this background, it is relevant to consider whether drug
resistance testing might have a role in monitoring people on ART
in the future in low and middle income settings, if a cheap test
could be developed. Such a test might perhaps detect only
NNRTI, or NNRTI and NRTI, resistance. Modelling studies
conducted in the context of South Africa have suggested that such
a test, if used in people for whom a raised viral load is detected to
determine whether a switch to second line is required (i.e. switch
only made if resistance is detected), would be cost effective, due to
the fact that savings in second line drugs would compensate for the
cost of the resistance testing [22,23]. Here we present results from
a model of HIV transmission, progression and the effect of ART,
which takes account of adherence and resistance in which we
compare the effectiveness and cost effectiveness of a range of
monitoring strategies which include resistance testing with those
that do not. We investigate this under three different contexts of
ART monitoring: clinical, with CD4 count or with viral load.
Methods
HIV Synthesis Transmission Model
The HIV Synthesis transmission model is an individual-based
stochastic model of heterosexual transmission, progression and
treatment of HIV infection which incorporates use of specific
drugs, resistance mutations, and adherence, and which has been
described previously [16,24,25]. Further details are provided in
the Methods and Results S1, with a detailed model description
previously published [25].
Scenario modelled
We simulated the progression of the HIV epidemic in adults in
Zimbabwe up to the beginning of 2015, based on comparisons
with data from Demographic and Health Surveys (DHS) and
other sources [26–29]. We assumed up to 2015 that CD4 counts
were used to monitor people on first line, and then considered the
introduction of various alternative monitoring strategies after
2015. We compared predicted outcomes over the period 2015 to
2025 in terms of viral suppression, first line failure, switching to
second line regimen, death, incidence, disability adjusted life years
averted and costs. One single simulation run was used up to 2015.
When comparing scenarios from 2015–2025 over 300 runs were
made for each strategy and means taken, which effectively
eliminates stochastic effects.
The evaluated monitoring strategies compared are shown in
Figure 1. We classify strategies according to the basic underlying
monitoring, which can be clinical (detection of presence of two
WHO stage 3 within 1 year or a WHO stage 4 disease, beginning
from 1 year after ART initiation), CD4 count-based (6 monthly,
beginning 1 year from ART initiation), or viral load-based (6
months, 12 months and then annually). Within each we consider a
strategy in which no further measures are performed, one in which
a viral load measure is done to confirm failure (with failure
declared only if the value is.1000 copies/mL), and one in which
both a viral load measure and (if viral load is.1000 copies/mL) a
resistance test are done (with failure declared only if the value is.
1000 copies/mL and NNRTI resistance is detected). To allow us
to get an appropriately broad perspective on alternative monitor-
ing options, we compare them with a reference scenario in which
no monitoring is performed and no second line regimen is
available. The detection of first line failure does not automatically
mean that the person will be switched to second line regimen. We
assume that after first line failure, according to whichever strategy
is being used, the probability of switching to second line is 0.3 per
3 months. This is much higher than the pre-2015 figure (of 0.03),
based on the relatively small numbers of people on second line in
Zimbabwe (reflecting that the switch criteria appear to be
implemented only very slowly), but was chosen to be similar to
the value reported in the UK [30] so that the different effects of
the strategies could be fully discerned.
Economic Analysis
The health benefits associated with the alternative policies were
estimated on the basis of disability adjusted life years (DALYs)
averted. We assume the objective is to maximize health and that
there are no costs incurred with the change in strategy. Costs
(presented in 2014 US$) were estimated based upon resource use
in the delivery of the policies (see Table S1 in Methods and Results
S1). We assumed fully-loaded costs for viral load ($15) and CD4
count ($8) measures in line with what might be hoped to be the
costs of available tests in the future, particularly with the
availability of point of care alternatives, and of resistance tests
($30). By fully-loaded, we mean inclusion of all costs to the health
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Figure 1. Monitoring strategies and switch criteria.
doi:10.1371/journal.pone.0109148.g001
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system required to make the test available and the result delivered
to the patient, including personnel and other overhead costs. The
time horizon for the analyses is 10 years from 2015 to 2025 (from
2015–2035 in one sensitivity analysis), and both costs and health
benefits are discounted to present value using a 3.5% per annum
discount rate.
The expected costs and health outcomes (DALYs averted)
associated with each of the policy alternatives can be compared to
inform which is likely to represent best value from available
resources. We present results by plotting the DALYs averted (on
the X axis) compared with a policy of no monitoring and no
second line, and increment in cost expressed in US dollars (on the
Y axis). We draw the cost-effectiveness frontier joining the
strategies with most DALYs averted per dollar spent. The slopes
of the component lines in the frontier represent the incremental
cost effectiveness ratio (ICER) for moving from one strategy to the
next most cost-effective option, when moving up and right. To
inform the allocation of resources within public health care
systems, and thus determine how far along the frontier to go from
the origin to choose the optimal strategy one should stop at, it is
necessary to know the cost- effectiveness threshold. The cost
effectiveness threshold for a country represents the opportunity
costs of resources required to fund the intervention, in terms of the
health gains those resources could generate if used for alternative
purposes in the public health care system [31]. As such, the
threshold for a country is not readily apparent, but is likely to be
well below $1000 per DALY averted in several countries in sub
Saharan Africa, especially when large coverage gaps for ART and
other basic interventions exist. Health utilities/disability weights to
calculate DALYs averted were derived from a recent comprehen-
sive study [32]. Several one way sensitivity analyses were
performed to examine the influence of various parameter values.
Results
Status of the population in 2015
Table 1 shows the situation for the simulated population at the
beginning of 2015, the year from which the various alternative
monitoring strategies are compared. Of those on ART, a high
proportion (85%) have viral load ,500 cps/mL, 13% have failed
first line, according to the CD4 count monitoring strategy assumed
to be used before 2015, but only 7% have started second line, due
to a low rate of switch in those with first line failure. Of those on
ART with viral load .500, 76% have NNRTI resistance.
Predicted outcomes according to monitoring strategy
Figure 2 shows outcomes (mean over 2015–2025) according to
monitoring strategy. The proportion of ART-experienced people
identified as having failed first line, according to the specific
criteria for the strategy, is generally highest with the viral load
monitoring strategies, intermediate with the CD4 count monitor-
ing strategies, and lowest with the clinical monitoring strategies.
The proportion who failed first line in the strategy where there is
no monitoring from 2015 is a reflection of those who had already
failed by 2015 and remain alive. Use of viral load to confirm
failure results in a lower proportion identified as failing first line,
but there is relatively little difference with additional confirmation
with a resistance test.
The proportion of people with viral suppression is predicted to
be highest with viral load monitoring without confirmation. The
mean proportion of people initiating ART who have transmitted
drug resistance is predicted to be lowest with use of viral load
monitoring, but the additional use of the resistance test does not
result in a lower proportion. HIV incidence in the population is
not predicted to differ much by strategy although it is lowest with
the viral load monitoring strategy (without confirmation with a
second viral load). The total discounted DALYs averted is also
shown, highest for the viral load monitoring strategy without
confirmation.
Costs of strategies
Figure 3 shows the breakdown of costs according to strategy,
which indicates that, at the low unit costs assumed, monitoring
costs make up a relatively small proportion of all HIV programme
costs, with viral load test costs being 4% of total treatment and
care costs for viral load monitoring-based strategies, and resistance
test costs, for strategies involving their use, being below 1%.
Focussing on the comparison between the strategy with viral load
monitoring (with viral load confirmation) with that using viral load
monitoring with both viral load and resistance testing, the
reduction in ART cost with the use of resistance testing is around
$6 m, while the cost of the resistance tests themselves is $4.5 m,
making the overall costs very similar. The increment in total cost
for each strategy compared with the reference strategy is shown in
Figure 2.
Cost effective frontier
Figure 4 shows the incremental costs and DALYs averted
compared with the strategy of no monitoring and no second line
availability. Generally, strategies that are based on viral load
monitoring avert most DALYs, followed by strategies based on
CD4 count monitoring while strategies based on clinical moni-
toring result in least DALYs averted. However, strategies involving
use of resistance testing to confirm failure do not appear to offer
clear advantages compared with strategies that do not. In this
assessment, viral load monitoring, with confirmation, becomes cost
effective at a cost effectiveness threshold of $2113, with further
DALYs averted at the same ICER with use of a single viral load
without confirmation.
In a further analysis we concentrated on the comparison
between the strategy with viral load monitoring (with viral load
confirmation) with that using viral load monitoring with both viral
load and resistance testing. For those with confirmed viral load .
1000 cps/mL but no resistance present we compared the status
after 1 year, according to these two strategies. Without resistance
testing the proportions who (i) remained on first line ART and had
viral load ,1000 copies/mL, (ii) remained on first line ART and
had viral load$1000 copies/mL, (iii) had started second line ART
and had with viral load ,1000 copies/mL, (iv) remained on first
line ART and had viral load$1000 copies/mL, (vi) were off ART,
or (vi) were dead, were, respectively, 5%, 20%, 46%, 8%, 10%
and 10% (i.e. 51% on ART with viral load ,1000 copies/mL).
The corresponding percentages using resistance test confirmation
were 39%, 23%, 12%, 6%, 11% and 10% (i.e. the proportion on
ART with viral load ,1000 copies/mL is similar).
Sensitivity analyses
We conducted several one way sensitivity analyses to see if the
main findings would differ, when varying the assumptions most
likely to influence these results (Figure 5). In none of the following
situations did the overall conclusions change: (a) a poorer overall
population adherence profile (so that only 76% had on average an
adherence above 80%, compared with 89% in the main analysis)
(b) a 20 year time horizon (c) a resistance test cost of $15 instead of
$30 (d) with the cost of bPI halved and (e) initiation of ART at
CD4 count below 500/mm3 rather than 350/mm3 and consid-
ering a scenario where boosted PI drugs have the same (instead of
higher, as in base case) potency as other drugs, and risk of
Cost-Effectiveness of Resistance Testing for ART Monitoring
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resistance accumulation is similar to NNRTI drugs (rather than
lower, as in base case). Results from further sensitivity analyses are
shown in Figure S1 of Methods and Results S1.
Discussion
We evaluated whether availability of a relatively cheap drug
resistance test might appreciably increase the effectiveness of adult
ART monitoring in low income settings and be cost effective. We
were unable to identify that this would be the case. This is in
contrast to the conclusion reached in modelling studies conducted
by Rosen et al [22] and Levison et al [23], who concluded that use
of resistance testing at first line virologic failure would be cost
effective in South Africa and potentially also in lower income
settings, due to the fact that people with no drug resistance would
not be put onto expensive second line boosted PI regimens. The
difference in findings partially relates to differences in modelled
outcomes for people who do not have resistance detected at first
line failure. Levison et al assume that a proportion of patients in
this situation subsequently achieve durable viral suppression on
first line ART and thereafter have the same outcomes as those
with initial virologic success [23]. Our model predicts that for a
person with virologic failure but no resistance mutations outcomes
are generally better if a switch to second line is made than if it is
not. This prediction is due to the strong person-specific component
to adherence, the fact that the improvement in adherence that is
triggered by a high viral load measurement may be temporary,
and the fact that the second line regimen is more forgiving of
intermittent adherence because the rate of emergence of resistance
to ritonavir boosted protease inhibitors is low [33,34]33,34 and
potency is high, given the ability to suppress viral load when used
as a single drug (albeit not to the same extent as a triple
combination of drugs) [35]. The prediction is consistent with the
recommended course of action in some treatment guidelines [5]
but there is little direct evidence. Data on outcomes for people who
have a non-suppressed viral load but no resistance mutations
detected, according to whether a switch is made to second line,
would be useful for further informing models in this area. Ideally, a
randomized trial might be performed.
The pattern of our results was generally similar in sensitivity
analyses (Figure 5). When considering a 20 year time horizon
(instead of 10) and of a situation in which adherence levels were
lower, differences in DALYs averted between strategies increased,
but the relative ordering generally remained very similar.
We assumed that if a resistance test is performed in a person
failing a first line regimen then the decision whether to switch
would be based on whether NNRTI resistance is present. One
could consider also basing the decision on presence of specific
nucleoside reverse transcriptase inhibitor mutations, for example
to tenofovir or zidovudine, but this would seem unlikely to change
our results since NNRTI mutations tend to appear most readily.
While our model does not suggest a key role for resistance tests in
monitoring of people on ART to decide on switching from first to
second line regimens, there are other future potential applications
of resistance tests which should be considered and which mean
that development of cheap, perhaps point of care, resistance test
might be valuable. For example, as the proportion of attendees at
ART initiation clinics who have NNRTI drug resistance grows,
either due to transmitted drug resistance or possibly previous
undeclared ART use, it could become cost effective to perform
individual level resistance testing before therapy initiation to
decide on which starting regimen to use in individuals, perhaps at
least in some middle income settings. Another modelling study has
previously suggested that such testing would not be cost effective
unless levels of transmitted drug resistance are very high [36]. At
least one trial is on-going in this area, in Kenya [37]. There could
Table 1. Characteristics of the population at baseline at beginning of 2015 (adults 15–65 years old).
Indicator Data sources*
HIV incidence (per 100 person
years)
0.61 0.67 in 2011 Spectrum [27]
HIV prevalence (age 15–45) 11% 15% in 2011 DHS [28]
% with transmitted NNRTI
resistance at ART initiation
9% 3%–22% (2008–2010) [39]
% diagnosed 89% Inferred based on 550,000 adults on ART in 2012
(,50% of all HIV+) [27,29]
Of diagnosed, % on ART 66% As above
Of diagnosed, % ART experienced 76% Percentage of adults and children with HIV known
to be on treatment 12 months after initiating antiretroviral
therapy 85.7% according to the NAC October 2009 Cohort
data that was analysed in 2010 [27]
% of all HIV+ on ART 59% 550,000 adults on ART in 2012 (,50% of all HIV+)
[27,29]
% of people on ART with VL ,500 85% [39]
% of ART experienced people
with VL ,500
77% [39]
% of those on ART failed first line 13% No data found
% of ART experienced people
who started second line
7% WHO reports 4% in LMICs
Of those on ART with viral
load.500, % with NNRTI
resistance
76% [39]
*note the data are given to enable comparison with simulated indicators – model is not formally calibrated to observed data in the references.
doi:10.1371/journal.pone.0109148.t001
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also be a future role of resistance testing in patients failing second
line regimens. Further, there could well be a more cost-effective
role for resistance testing in routine care in selecting drug regimens
for pregnant women who are not on ART at pregnancy
presentation, since it is important to select a regimen that will
maximise the chance of viral suppression at the time of birth.
Again, this was not formally evaluated here.
We assumed that monitoring strategies would be carried out
perfectly, so that all people in care are monitored as indicated in
the guidelines, that all measurement results are returned to the
Figure 2. Outcomes by monitoring strategy. Mean over 2015–2025 (except for cost and DALYs where total over this period is given). VL - viral
load.
doi:10.1371/journal.pone.0109148.g002
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clinic within the necessary time, that the health workers
responsible for monitoring people on ART correctly implement
the switch algorithm, and that the probability of switch given first
line failure is independent of the failure definition. In future work
comparing monitoring strategies it will be important to assess the
impact of real life challenges with implementation as this may
result in favouring of simpler more robust monitoring approaches.
So far, rates of switching to second line regimens have been low in
African settings [38]. Further, although our model is extensively
calibrated to multiple data sources to ensure that we capture the
dual influences of adherence and resistance on viral load level, as
with any modelling analysis there is the possibility that this does
not fully capture the critical elements of the underlying process
necessary to reach correct conclusions over the comparisons made.
As further data emerges we can revisit this question, if necessary
amending our model as newly emerging data point to any mis-
specified elements.
Figure 3. Breakdown of costs by strategy - total discounted cost 2015–2025, in $million. See Figure 1 for legend for strategies.
doi:10.1371/journal.pone.0109148.g003
Figure 4. Incremental costs and DALYs averted for monitoring strategies over 10 years, compared with no monitoring, no second
line. See Figure 1 for legend for strategies.
doi:10.1371/journal.pone.0109148.g004
Cost-Effectiveness of Resistance Testing for ART Monitoring
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e109148
Cost-Effectiveness of Resistance Testing for ART Monitoring
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e109148
In conclusion, we did not identify a compelling role for drug
resistance testing as part of ART monitoring in making the
decision whether to switch from first to second line.
Supporting Information
Methods and Results S1 Supplementary methods, tables
and figures, and parameter values and costs.
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